Project Grant R43HL137453

This $499,103 federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) is supporting Alleviant Medical, Inc.'s efforts to advance the commercial readiness of their no-implant interatrial shunt therapy for treating heart failure. The key objectives are to implement high-volume manufacturing capabilities, establish production readiness for the ALV1 system, and execute reimbursement and marketing...

Percassist Inc. received a $663,129 Project Grant award from the National Heart Lung and Blood Institute of the Department of Health and Human Services. The award was made under the Cardiovascular Diseases Research program (CFDA 93.837), which supports heart and vascular research. The grant funds the development of a percutaneous ventricular assist device for chronic heart failure patients. Specifically, Percassist will design and test a balloon catheter implant that can be delivered minimally...

The National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), awarded a $790,738 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Circulatech LLC, a for-profit limited liability company located in Pembroke Pines, Florida. The grant will fund the development and evaluation of Circulatech's Thoraflush, a proactive chest tube system that utilizes dual irrigation technology to maintain drainage patency and prevent...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), aims to investigate the mechanical and hemodynamic performance of a novel pulmonary visceral pleura (PVP) bioprosthetic aortic valve. The total funding amount is $742,323, awarded on December 15, 2024, with an ultimate completion date of November 30, 2028. The research approach involves in vitro experiments, computational modeling, and in vivo...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $676,970 to the Geisinger Clinic in Danville, PA to investigate the effects of continuous versus pulsatile blood flow on blood trauma, arterial remodeling, and vasoregulation in a chronic bovine model using the BiVACOR total artificial heart. The research aims to determine if pulsatile flow can reduce adverse events associated with...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $437,461 to 3DT Holdings, LLC, a minority-owned biomedical engineering company, to develop a novel stabilization catheter for His pacing lead implant. The goal is to refine the design of a deployable suction flute-tipped lead placement sheath to improve the mapping and placement of His leads, which are used in cardiac resynchronization...

This $595,464 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the development of Cerulean Scientific Inc.'s tethered liquid perfluorocarbon (TLP) coating technology for peripheral vascular grafts (PVGs). The funding will enable Cerulean to conduct in vitro characterization studies on the durability and anti-fouling properties of the TLP coating, as well as in vitro thrombogenicity testing. In...

Starlight Cardiovascular, Inc. was awarded a $1,477,713 Project Grant from the National Heart, Lung, and Blood Institute's Cardiovascular Diseases Research program to develop the first FDA-approved stent designed specifically for ductus arteriosus. The ductus arteriosus is a natural blood vessel that remains open in infants born with certain congenital heart defects; currently there are no stents approved for this use, forcing clinicians to repurpose adult coronary stents which have a high 47%...

This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $704,672 to develop an implantable device to improve vascular access and safety for hemodialysis patients. The device features a 3D-printed titanium shell that guides the hemodialysis needle to the correct insertion point, and a titanium-nitride coated valve that stops bleeding upon...

This $256,000 National Science Foundation project grant supports the development of an automated chest tube to prevent clotting. Circulatech LLC will design and prototype a novel chest tube that proactively manages fluid flow within the catheter lumen to flush and drain the tube, reducing blood clot formation. Through a process called "dilutional coagulopathy," the tube will use sterile saline or anticoagulants to reduce thrombosis in the drainage space rather than relying on...